Precision BioSciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for DTIL, updated each market day.
DTIL AI Sentiment
AI sees no strong directional signal for Precision BioSciences, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Precision BioSciences, Inc. Common Stock
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Sector
Exchange
Market Cap
$199,835,250
Cap Tier
Employees
67
Headquarters
DURHAM, NC
Listed Since
March 28, 2019
DTIL Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
DTIL Volatility
Precision BioSciences, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
